ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib were presented a the American Society for Clinical Oncology (ASCO) Annual Meeting over the weekend. The nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice […]

read more

New risk scoring system for metastatic kidney cancer

The treatment options for metastatic renal cell carcinoma (RCC) have changed considerably over the past 10 years with the introduction of immunotherapies, such as nivolumab, ipilimumab and pembrolizumab. However, with the new treatments comes the challenge of selecting the most effective treatment for each individual patient. Clinicians are constantly looking for ways to discover which […]

read more

Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC). Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, […]

read more

Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer

A paper published in The Oncologist last month analysed real-world data to further evaluate the effectiveness of first-line sunitinib in patients with metastatic renal cell carcinoma (mRCC) with favourable, intermediate or poor risk disease according to the International mRCC Database Consortium (IMDC) risk criteria. The study included 1769 patients; 318 (18.0%) had favourable risk, 1031 […]

read more

Regular exercise reduces risk for 7 different cancers

A new study published in Journal of Clinical Oncology suggests that the more your exercise, the lower your risk of developing any of seven different types of cancer. Researchers pooled the data from nine published studies involving more than 750,000 people. “We found that the recommended amount of physical activity was in fact associated with […]

read more

Being overweight before the age of 40 increases cancer risk

A recent international study, lead by the University of Bergen in Norway, found that being overweight (BMI over 25) or obese (BMI over 30) before the age of 40 can increase the risk of different types of cancer. The study showed that if you were overweight before age 40, the risk of developing cancer increases […]

read more

Higher vitamin D levels associated with lower likelihood of kidney cancer

A new study, published in the International Brazilian Journal of Urology, shows that higher circulating concentrations of 25-hydroxyvitamin D in the blood are associated with a lower risk of renal cell carcinoma (RCC). The study, conducted in China, compared 135 newly diagnosed cases of RCC with 135 controls matched by age and sex. The investigators […]

read more

Incidence of some obesity-related cancers in increasing in younger people

A recent study, published in The Lancet Public Health, has shown that there was a significant increase in incidence for six obesity-related cancers (multiple myeloma, colorectal, uterine corpus, gallbladder, kidney, and pancreatic cancer) in adults age 25 to 49 years. In addition, the increase in incidence was steeper in successively younger generations. For people aged […]

read more

Immunoscore system to predict kidney cancer patient outcomes

A recent study by researchers in China, and published in the Journal of Cancer, assessed the¬†Immunoscore system to determine if it can predict survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The presence of various protein receptors on the cancer cells were analysed. Levels of protein receptors for […]

read more

New prognostic factor for metastatic renal cell carcinoma

A retrospective study has shown that a high systemic immune-inflammation index (SII) score is an independent indicator for poor overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). The researchers suggest that the neutrophil and platelet counts in the¬†International Metastatic Renal Cell Carcinoma Database Consortium¬†(IMDC) model to predict […]

read more
Showing 1 to 10 of 58 results
  TOP